Latest action: Referred to the Subcommittee on Health.
Referred to one or more standing committees for review, hearings, and possible markup.
Specific committees not parsed from action data.
The committee may hold hearings, amend the bill, or let it die without action.
Next: Reported
Full chamber floor — Speaker / Majority Leader controls scheduling
Bill aims to prevent drug companies from charging unfairly high prices for medications.
The problem
Patients struggle to afford prescription medications because pharmaceutical companies charge very high prices. Some medications cost significantly more in the U.S. than other countries.
The proposal
The bill would give the government power to review and potentially limit how much drug companies can charge for prescription medications to prevent excessive pricing.
The impact
Patients would pay less for medications. Drug companies would face new restrictions. Healthcare providers and insurance companies would see changes in medication costs.
People struggling to afford prescriptions could access medicines more easily. This could improve health outcomes for lower-income Americans who skip doses or avoid filling prescriptions due to cost.
Lower drug prices mean government programs like Medicare and Medicaid spend less money. Insurance premiums might decrease, benefiting consumers and employers.
Americans would pay prices closer to what patients pay in Canada and Europe. This addresses the perception that U.S. drug prices are unfairly high.
Pharmaceutical companies would earn less revenue from medications. Lower profits might reduce money available for developing new drugs and treatments.
Drug companies invest profits into research for new medications. Price limits could slow development of treatments for rare diseases and new health conditions.
Giving government power to set drug prices is a major market intervention. This could set a precedent for government price controls in other industries.
If prices drop too low, drug manufacturers might stop producing less profitable medications, leading to shortages of certain drugs.
Generated by AI from the bill text. Not a prediction and not legal or policy advice. The percentage is the model's own rating of each item — self-reported, and not a measure of how accurate it is.
Loading map…
Loading...
0 citizens have already voted
Free · No spam · See how your representatives voted
Be the first to weigh in
Your vote starts the conversation
How citizen engagement works
Citizens vote & comment
Public opinion data is aggregated and updated in real time.
Patterns become visible
Representatives can see constituent sentiment broken down by district.
Your voice on the record
Contact your rep directly — one constituent call can shift a staffer's priority list.
Research shows that constituent contacts — especially calls — are among the most effective ways to influence a legislator's position on active bills.
Individual contributions, grouped by employer · FEC
Where their individual donors work · 2026 cycle
Money from people who work there, not from the company. Not tied to this bill.
Itemized individual contributions via FEC, grouped by the employer each contributor self-reported. Companies and unions cannot contribute to federal candidates from their treasuries, so these totals are money from people who work at an employer — never from the organization itself. They are campaign contributions covering a full election cycle and are not connected to this bill.
Senate LDA lobbying disclosures
Couldn't load lobbying disclosures right now.